|

Liposomal doxorubicin Clinical Trials

6 actively recruiting trials across 6 locations

▲ +1 trial since July 2026

Also known as: Caelyx, DOX, DOXIL®, Doxil®, Lipodox +1 more

Pipeline

Phase 1: 1Phase 2: 3Phase 3: 2

Top Sponsors

  • Merck Sharp & Dohme LLC2
  • Northwestern University1
  • Memorial Sloan Kettering Cancer Center1
  • H. Lee Moffitt Cancer Center and Research Institute1
  • Beth Israel Deaconess Medical Center1

Indications

Birmingham, Alabama1 trial

Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

University of Alabama at Birmingham (Children's of Alabama)

Phase 1

Daphne, Alabama1 trial

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Southern Cancer Center (SCC) ( Site 8000)

Phase 3

Chandler, Arizona1 trial

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Ironwood Cancer & Research Centers ( Site 0066)

Phase 3

Duarte, California1 trial

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

City of Hope Cancer Center (Data Collection Only)

Phase 2

Chicago, Illinois1 trial

Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

Northwestern University

Phase 2

Boston, Massachusetts1 trial

The CARDIOPROTECT Trial

Beth Israel Deaconess Medical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.